Home > Technical section > minimal residual disease detection

minimal residual disease detection

Monday 28 November 2011

References

- Stability of PCR Targets for Monitoring Minimal Residual Disease in Neuroblastoma. Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. J Mol Diagn. 2012 Jan 14. PMID: 22251610

- Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma. Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE. Clin Cancer Res. 2012 Feb 1;18(3):808-14. PMID: 22142825

- Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. Clin Chem. 2009 Jul;55(7):1316-26. PMID: 19460840